Cinryze Launch Plans Bear Hallmarks Of Successful Orphan Strategies

ViroPharma/Lev scored a regulatory success with FDA's approval of Cinryze (C1 esterase inhibitor) for prophylaxis of hereditary angioedema. Now the firm needs to concentrate on turning that into a commercial success - and with the launch plans recently laid out, the firm seems poised to do that

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet